clinic
microbiolog
infect
xxx
xxxx
xxx
pleas
cite
articl
brendish
nj
et
al
syndrom
panel
panel
syndrom
perspect
len
respiratorytract
infect
zanella
et
al
clinic
microbiolog
infect
http
doi
read
interest
articl
zanella
et
al
author
suggest
increas
use
rapid
autom
syndrom
molecular
panel
respiratori
virus
rv
abandon
favour
limit
pcr
test
rv
eg
test
influenza
alon
influenza
rsv
combin
due
high
cost
uncertain
clinic
impact
detect
noninfluenza
virus
articl
repeatedli
call
evidencebas
approach
rv
diagnost
test
cite
lack
evid
clinic
impact
costeffect
syndrom
rv
panel
justif
posit
howev
attempt
systemat
review
literatur
instead
present
data
select
paper
neglect
review
discuss
import
element
current
evid
base
feel
issu
central
debat
acut
unwel
patient
hospit
neither
test
syndrom
panel
limit
rv
test
use
result
deliv
clinic
infect
control
team
meaning
time
frame
sever
studiesdinclud
random
control
trial
rct
shown
laboratori
pcr
result
rv
lead
chang
clinic
manag
result
avail
h
later
standard
turnaround
time
rv
test
hospit
laboratori
compar
test
sens
current
laboratorybas
pcr
test
rv
either
syndrom
panel
limit
test
fact
call
evidencebas
costeffect
comparison
grow
bodi
evid
observ
studi
rct
clinic
impact
costeffect
molecular
pointofcar
test
mpoct
rv
syndrom
panel
limit
rv
test
studi
demonstr
consist
benefit
compar
laboratori
test
hospit
patient
respoc
rct
brendish
et
al
demonstr
syndrom
test
rv
point
care
result
avail
h
compar
syndrom
laboratori
pcr
result
avail
around
h
associ
sever
improv
clinic
manag
includ
patient
treat
brief
cours
antibiot
reduct
length
hospit
stay
direct
influenza
antivir
better
use
isol
facil
benefit
depend
short
turnaround
time
tat
result
best
tat
h
achiev
central
laboratori
health
econom
analysi
respoc
trial
also
suggest
syndrom
mpoct
fact
costsav
compar
central
laboratori
test
worst
costneutr
way
definit
assess
ad
valu
syndrom
rv
mpoct
compar
limit
rv
mpoct
would
evalu
impact
headtohead
rct
date
done
respoc
trial
howev
give
us
import
insight
potenti
advantag
syndrom
test
limit
rv
test
point
care
studi
patient
posit
result
rv
mpoct
antibiot
stop
earlier
neg
patient
rhino
enteroviru
frequent
detect
viru
type
influenza
mani
patient
exacerb
airway
diseas
addit
third
patient
antibiot
stop
earli
either
hmpv
parainfluenza
coronaviru
adenoviru
detect
test
influenza
influenza
rsv
would
result
earli
antibiot
discontinu
seen
trial
reduct
length
stay
seen
respoc
trial
similarli
due
earli
discharg
proport
patient
also
occur
predominantli
patient
test
posit
virus
antibiot
chang
associ
wide
rang
rv
influenza
would
occur
limit
rv
test
final
also
clear
addit
advantag
alreadi
discuss
test
broad
rang
pathogen
detect
syndrom
rv
panel
compar
limit
rv
test
includ
enabl
enhanc
infect
control
measur
noninfluenza
virus
may
also
associ
nosocomi
transmiss
high
risk
mortal
typic
elderli
comorbid
frail
patient
present
medic
ward
conclus
feel
ultim
purpos
diagnost
test
elucid
caus
patient
infect
rapidli
comprehens
possibl
inform
manag
protect
other
syndrom
test
perform
point
care
enabl
happen
accur
real
time
associ
improv
clinic
manag
rct
njb
conceiv
letter
outlin
first
draft
twc
led
write
manuscript
sp
contribut
manuscript
author
contribut
agre
final
version
manuscript
write
editori
assist
use
articl
twc
report
grant
nation
institut
health
research
nihr
drive
eu
person
fee
biomerieux
biofir
diagnost
roch
cidara
therapeut
synairgen
randox
laboratori
nonfinanci
support
biomerieux
biofir
diagnost
njb
sp
conflict
interest
declar
njb
support
nihr
clinic
lectur
scheme
sp
support
nihr
southampton
biomed
research
centr
doctor
fellowship
twc
support
nihr
postdoctor
fellowship
view
opinion
express
manuscript
author
necessarili
reflect
nihr
nh
depart
health
fund
receiv
work
